Butisol

Butisol

 [bu´tĭ-sol]
trademark for preparations of butabarbital, a barbiturate.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

butabarbital

A fast-acting sedative/hypnotic of intermediate duration of action.
 
Adverse effects
Drowsiness, insomnia, nightmares, headaches, dizziness, depression, excitability, restlessness, nausea, vomiting, constipation, dyspnoea.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.

Butisol®

Butabarbital, see there.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
The agency requested the labeling changes for the following medications: Ambien/Ambien CR, Butisol Sodium, Carbrital, Dalmane, Doral, Halcion, Lunesta, Placidyl, Prosom, Restoril, Rozerem, Seconal and Sonata.
The label change affects drugs including Zolpidem, marketed as Ambien/Ambien CR by Sanofi-Aventis; butabarbital, marketed as Butisol Sodium by Medpointe Pharmaceuticals HLC; flurazepam, marketed as Dalmane by Valeant Pharmaceuticals; quazepam, marketed as Doral by Questcor Pharmaceuticals; triazolam, marketed as Halcion by Pharmacia & Upjohn Inc.; eszopiclone, marketed as Lunesta by Sepracor Inc.; estazolam, marketed as Prosom by Abbott; temazepam, marketed as Restoril by Tyco Healthcare Group; ramelteon, marketed as Rozerem by Takeda Pharmaceutical Inc.; secobarbital, marketed as Seconal by Ranbaxy Pharmaceuticals Inc.; and zaleplon, marketed as Sonata by King Pharmaceuticals Inc.
The label change affects drugs including Zolpidem, marketed as Ambien/Ambien CR by Sanofi-Aventis; butabarbital, marketed as Butisol Sodium by Medpointe Pharmaceuticals HLC; flurazepam, marketed as Dalmane by Valeant Pharmaceuticals; quazepam, marketed as Doral by Questcor Pharmaceuticals; triazolam, marketed as Halcion by Pharmacia & Up-john Inc.; eszopiclone, marketed as Lunesta by Sepracor Inc.; estazolam, marketed as Prosom by Abbott; temazepam, marketed as Restoril by Tyco Healthcare Group; ramelteon, marketed as Rozerem by Takeda Pharmaceutical Inc.; secobarbital, marketed as Seconal by Ranbaxy Pharmaceuticals Inc.; and zaleplon, marketed as Sonata by King Pharmaceuticals Inc.
In 1988, HQ finally threw caution to the winds and published a straight-forward Drug Dosage Table listing the lethal dosages of eighteen common prescription drugs: Amytal, Butisol, Valium, Dalmane, Doriden, Noctec, Dilaudid, Miltown, Noludar, Demerol, Dolophine, Norflex, Seconal, Nembutal, Darvon, codeine, morphine, and phenobarbital.